D89.82 Autoimmune lymphoproliferative syndrome [ALPS]

Name of the Condition

• Autoimmune lymphoproliferative syndrome [ALPS]

Summary

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder characterized by abnormal lymphocyte proliferation and dysregulated immune function, leading to chronic lymphadenopathy, splenomegaly, and autoimmune manifestations. It results from defects in apoptosis pathways, particularly involving the FAS-mediated cell death mechanism, which impairs the body’s ability to eliminate self-reactive lymphocytes. The condition typically presents in childhood or adolescence, with symptoms ranging from mild to severe, and may require long-term management to address immune dysregulation and associated complications.

Causes

ALPS is caused by genetic mutations that disrupt apoptosis, most commonly in the FAS gene (TNFRSF6), though mutations in other genes like FASLG, CASP10, or NRAS may also contribute. These mutations impair the normal process of lymphocyte apoptosis, leading to the accumulation of autoreactive T and B cells. The condition is often inherited in an autosomal dominant pattern, though de novo mutations can occur. The exact genetic basis may vary, and not all cases have identifiable mutations, suggesting additional contributing factors or genetic heterogeneity.

Risk Factors

• Genetic mutations in apoptosis-related genes (e.g., FAS, FASLG)
• Family history of ALPS or related autoimmune disorders
• Age of onset (typically childhood or adolescence)
• Presence of autoantibodies or autoimmune manifestations
• Chronic lymphoproliferation (e.g., lymphadenopathy, splenomegaly)

Symptoms

• Persistent lymphadenopathy (enlarged lymph nodes)
• Splenomegaly (enlarged spleen)
• Autoimmune cytopenias (e.g., anemia, thrombocytopenia, neutropenia)
• Recurrent infections due to immune dysregulation
• Skin rashes or other autoimmune manifestations
• Fatigue or general malaise

Diagnosis

Diagnosis of ALPS involves a combination of clinical evaluation, laboratory testing, and genetic analysis. Key diagnostic criteria include chronic nonmalignant lymphoproliferation (e.g., lymphadenopathy, splenomegaly), elevated double-negative T cells (CD4-/CD8-), and evidence of defective lymphocyte apoptosis (e.g., increased Fas-mediated cell death resistance). Autoimmune cytopenias, elevated immunoglobulins, and family history may support the diagnosis. Genetic testing for mutations in FAS, FASLG, or other related genes can confirm the underlying cause, though absence of mutations does not exclude the condition.

Treatment Options

Treatment focuses on managing symptoms and complications. Immunosuppressive therapies, such as corticosteroids or mycophenolate mofetil, may be used to control autoimmune cytopenias. Splenectomy is sometimes considered for severe cytopenias or splenomegaly, though it carries risks of infection. Rituximab or other biologic agents may be employed for refractory cases. Regular monitoring of lymphocyte counts, autoimmune markers, and organ function is essential. Supportive care, including infection prevention and management of autoimmune manifestations, is also critical.

Prognosis and Follow-Up

The prognosis of ALPS varies, with most patients experiencing a chronic course. While the condition is not typically life-threatening, complications such as severe autoimmune cytopenias or lymphoproliferative disorders can occur. Long-term follow-up is necessary to monitor for disease progression, organ involvement, and treatment-related side effects. Regular assessments of lymphocyte subsets, autoimmune markers, and organ function help guide management. Early intervention and adherence to treatment plans can improve outcomes and quality of life.

Complications

• Severe autoimmune cytopenias (e.g., life-threatening anemia or thrombocytopenia)
• Increased risk of lymphoma or other lymphoproliferative disorders
• Chronic infections due to immune dysregulation
• Organ damage from prolonged inflammation or autoimmune activity
• Treatment-related complications (e.g., infection from immunosuppression)

Lifestyle & Prevention

Lifestyle modifications may help manage symptoms and reduce complications. Patients should avoid known triggers of autoimmune flares and practice good hygiene to minimize infection risk. Regular exercise and a balanced diet support overall health, though specific dietary restrictions are not typically required. Vaccinations (excluding live vaccines) are recommended to prevent infections, and patients should avoid contact with individuals with contagious illnesses. Stress management and regular medical follow-up are also important for maintaining well-being.

When to Seek Professional Help

Seek medical attention if symptoms worsen, such as increasing fatigue, unexplained bleeding (e.g., bruising, nosebleeds), or signs of infection (e.g., fever, chills). Prompt evaluation is necessary for new or worsening autoimmune manifestations, such as jaundice or severe anemia. Emergency care is warranted for acute complications, including severe cytopenias or organ dysfunction. Regular follow-up with a hematologist or immunologist is essential for ongoing management.

Tips for Medical Coders

When coding for autoimmune lymphoproliferative syndrome (ALPS), use ICD-10-CM code D89.82. Ensure documentation supports the diagnosis, including clinical findings (e.g., lymphadenopathy, splenomegaly), laboratory results (e.g., elevated double-negative T cells), and genetic testing if performed. Note any associated autoimmune cytopenias or complications, as these may require additional coding. Verify that the code is not used for other lymphoproliferative or autoimmune disorders, and confirm the specificity of the diagnosis to avoid miscoding.